Frontlight ResearchEarly access
Active, not recruitingPhase 2
Evaluating Cannabidiol as a Novel Anticraving Medication for Alcohol Use Disorder
Key facts
- Who runs it
- Centre for Addiction and Mental Health
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 2
- People taking part
- 36 people, planned
- Started
- 16 Aug 2024
- Expected to end
- 31 Jan 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Oral solution
- Record updated
- 2 November 2026
Who can take part
- Age
- 19 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- Meets DSM-5 criteria for AUD
- Meets drinking criteria of average weekly consumption > 10 standard drinks for women and > 15 standard drinks for men over the past 90 days
- Willing to take study medication and participate in laboratory sessions requiring self-administration of alcohol
- Agrees not to use cannabis or illicit drugs during the study period
- Able to communicate and provide informed consent in English
- Alanine Aminotransferase (ALT) and Aspartate Transaminase (AST) level should not be more than 2 times the upper normal limit, and bilirubin should not be more than 1.5 times the upper normal limit
- Enrolled in the Ontario Health Insurance Plan (OHIP)
- Willing and able to safely abstain from alcohol for at least 12 hours prior to the eligibility and alcohol self-administration visit
- Individuals who are capable of becoming pregnant: agree to the use of highly effective contraception during study participation and for an additional 28 days after the end of cannabidiol administration
Who cannot take part
- Having any clinical condition, drug sensitivity, or prior therapy which, in the investigator's opinion, makes the participant unsuitable for the study
- Current medical conditions, prescriptions, or over the counter medications that interfere with receiving the study drug or alcohol (based on the study physician's assessment)
- Recent recreational drug use (assessed via urine toxicology screen) other than alcohol and nicotine products
- Currently in treatment for AUD (e.g. Alcoholics Anonymous, group therapy, individual therapy, on anticraving medication)
- History of severe alcohol withdrawal including withdrawal seizures, alcoholic hallucinosis, or delirium tremens
- Any history of seizures
- Serious unstable medical condition, including severe hepatic abnormalities
- Severe mental illness (e.g. active psychosis with ongoing delusions and/or hallucinations, active manic or hypomanic episodes, evidence of a major neurocognitive disorder, etc.) and other substance use disorders (moderate or severe; excluding tobacco use disorder) as determined by the qualified investigator
- History of hypersensitivity to CBD
- Clinical Institute Withdrawal Assessment (CIWA-Ar) score of 10 or above upon initial assessment
- Experiencing active suicidal ideation within the past 1 month and/or suicide attempt within the past 6 months
- Current use of CBD products or use of CBD products within the past month
- Self-report of significant alcohol-induced flushing after 1-2 drinks (a proxy for aldehyde dehydrogenase deficiency)
- Currently pregnant or breastfeeding or intending to become pregnant or breastfeed
- Currently institutionalized which refers to a person who lives in an institutional collective dwelling, such as a hospital, nursing home or prison, including a resident under custody (e.g., patient or inmate)
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This human laboratory study aims to assess the effects of cannabidiol on alcohol consumption and craving in participants with alcohol use disorder. In this double-blind within-subject placebo-controlled crossover trial, participants will be randomized to receive both cannabidiol and placebo with a 2-week washout period separating the two treatment phases.
The 2 groups in the trial
- CannabidiolTreatment being tested
10-day supply of 600 mg of CBD, taken orally twice daily
Treatment: Oral solution
- PlaceboPlacebo, for comparison
10-day supply of 600 mg of placebo, taken orally twice daily
Treatment: Oral solution
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Evaluating Cannabidiol as a Novel Anticraving Medication for Alcohol Use Disorder: A Human Laboratory Study
- Record updated
- 2 November 2026